Bromocriptine versus levodopa in early Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Van Hilten, J J ^a   Ramaker, C C ^b   Stowe, R L ^b   Ives, N J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Antiparkinson agents adverse effects; *therapeutic use ; Bromocriptine *therapeutic use ; Human; Levodopa adverse effects; *therapeutic use ; Parkinson disease *drug therapy ; Randomized controlled trials as topic

Indexed keywords

BROMOCRIPTINE; LEVODOPA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; HALLUCINATION; HUMAN; INFORMATION PROCESSING; MONOTHERAPY; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 44949246406     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002258.pub2     Document Type: Review

References (44)

1. Hely 1994 {published and unpublished data} Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, et al.The Sydney multicentre study of Parkinson's disease: The first 18 months. The Medical Journal of Australia 1987;146:195-8.
2. Hely MA, Morris JG, Rail D, Reid WG, O'Sullivan DJ, Willaimson PM, et al.The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52:324-8.
3. *Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, et al.The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing with low dose bromocriptine with low dose levodopa-carbidopa. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57:903-10.
4. Herskovits 1988 {published data only} Herskovits E, Yorio A, Leston J. Long term bromocriptine treatment in de novo Parkinsonian patients. Medicina (B Aires) 1988;48(4):345-50.
5. Olanow 1987 {published data only} Olanow CW, Alberts MJ, Stajich J, Burch G. A randomized blinded study of low-dose bromocriptine versus low-dose carbidopa/levodopa in untreated Parkinson's patients. In: FahnS, MarsdenD, CalneD, GoldsteinM editor(s). Recent developments in Parkinson's disease. Vol. II, New York: Macmillan Healthcare, 1987:201-208.
6. Riopelle 1988 {published and unpublished data} Riopelle RJ, Gawel MJ, Libman I, King DB, McLean DR, Paulseth R, et al.A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short term results. European Neurology 1988;28Suppl 1:11-4.
7. UK-PDRG 1993 {published and unpublished data} Lees AJ, Frankel J, Eatough V, Stern GM. New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta Neurologica Scandinavica. Supplementum 1989;126:139-45.
8. *Lees AJ. Comparison of therapeutic effects, mortality data of levodopa, levodopa combined with selegiline in patients with early. mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995;311:1602-7.
9. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-72.
10. Weiner 1993 {published and unpublished data} Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon RN, Cornelius L, et al.Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43(1):21-7.
11. Caraceni 2001 *Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicentre study. Parkinsonism and Related Disorders 2001;107:107-14.
12. Gawel 1987 Gawel M, Riopelle R, Libman I, Bouchard S. Bromocriptine in the treatment of Parkinson's disease: a double- blind study against L-dopa/ carbidopa. Advances in Neurology 1987;45:535-8.
13. Libman 1987 Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. The Canadian Journal of Neurological Sciences 1987;14:576-80.
14. Riopelle 1987 Riopelle RJ. Bromocriptine and the clinical spectrum of Parkinson's disease. The Canadian Journal of Neurological Sciences 1987;14(Suppl):S455-S9.
15. Wallis 1988 Wallis WE. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa. European Neurology 1988;28(Suppl 1):S9-S10.
16. Ahlsog 1994 Ahlskog JE.Treatment of Parkinson's disease. From theory to practice. Postgraduate Medicine 1994;95:52-4.
17. Begg 1996 Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al.Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9. [MEDLINE: 652].
18. Bernheimer 1973 Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of Neurological Sciences 1973;20(4):415-55. [MEDLINE: 622].
19. Calne 1974 Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of parkinsonism with bromocriptine. Lancet 1974;2(7893):1355-6. [MEDLINE: 621].
20. Canter 1961 Canter CJ, de la Torre R, Mier M. A method of evaluating disability in patients with Parkinson's disease. The Journal of Nervous and Mental Disease 1961;133:143-7.
21. Corrodi 1973 Corrodi H, Fuxe K, Hokfelt T, Lidbrink P, Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. The Journal of Pharmacy and Pharmacology 1973;25(5):409-12. [MEDLINE: 623].
22. de Rijk 1995 de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, et al.Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45(12):2143-6. [MEDLINE: 639].
23. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91. [MEDLINE: 624].
24. Factor 1993 Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Movement Disorders 1993;8(3):257-62. [MEDLINE: 158].
25. Goetz 1990 Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(10:Suppl 3):50-4. [MEDLINE: 709].
26. Goldstein 1983 Goldstein M, Engel J, Lieberman A, Regev I, Bystritsky A, Mino S. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists. Journal of Neural Transmission. Supplementum 1983;18:257-63. [MEDLINE: 627].
27. Hely 1987 Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, et al.The Sydney multicentre study of Parkinson's disease: The first 18 months. The Medical Journal of Australia 1987;146:195-8.
28. Hely 1989 Hely MA, Morris JG, Rail D, Reid WG, O'Sullivan DJ, Williamson PM, et al.The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52:324-8.
29. Hoehn 1967 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-42. [MEDLINE: 632].
30. Hornykiewicz 1966 Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews 1966;18(2):925-64. [MEDLINE: 633].
31. Lees 1989 Lees AJ. The on-off phenomenon. Journal of Neurology, Neurosurgery, and Psychiatry 1989;Suppl:29-37. [MEDLINE: 634].
32. Lees, Frankel 1989 Lees AJ, Frankel J, Eatough V, Stern GM.New approaches in the use of selegiline for the treatment of Parkinson's disease. Acta Neurologica Scandinavica. Supplementum 1989;126:139-45.
33. Luquin 1992 Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Movement Disorders 1992;7(2):117- 24. [MEDLINE: 641].
34. Marsden 1976 Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1(7954):292-6. [MEDLINE: 618].
35. Marsden 1982 Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: MarsdenCD, FahnS editor (s). Movement Disorders. London: Butterworths Scientific, 1982.
36. Parkinson's 1993 Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegine, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-72.
37. Poewe 1988 Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Annals of Neurology 1988;23(1):73-8. [MEDLINE: 636].
38. Schwab 1960 Schwab RS. Progression and prognosis in Parkinson's disease. The Journal of Nervous and Mental Disease 1960;130:556- 66.
39. Shaw 1980 Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. The Quarterly Journal of Medicine 1980; 49(195):283-93. [MEDLINE: 640].
40. UPDRS 1987 Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: FahnS, GoldsteinM, MarsdenD, CalneDB editor(s). Recent Developments in Parkinson's Disesase. Vol. II, New Jersey: MacMillan, 1987.
41. Watts 1997 Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology 1997;49(1:Suppl 1):S34-S48. [MEDLINE: 352].
42. Webster 1968 Webster DD. Critical analysis of the disability in Parkinson's disease. Modern Treatment 1968;5(2):257-82.
43. Yahr 1969 Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Archives of Neurology 1969;21(4):343-54.
44. Zhang 1993 Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12(4):195-208. [MEDLINE: 642].